Your browser doesn't support javascript.
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Visco, Carlo; Marcheselli, Luigi; Mina, Roberto; Sassone, Marianna; Guidetti, Anna; Penna, Domenico; Cattaneo, Chiara; Bonuomo, Valentina; Busca, Alessandro; Ferreri, Andrés José María; Bruna, Riccardo; Petrucci, Luigi; Cairoli, Roberto; Salvini, Marco; Bertù, Lorenza; Ladetto, Marco; Pilerci, Sofia; Pinto, Antonello; Ramadan, Safaa; Marchesi, Francesco; Cavo, Michele; Arcaini, Luca; Coviello, Elisa; Romano, Alessandra; Musto, Pellegrino; Massaia, Massimo; Fracchiolla, Nicola; Marchetti, Monia; Scattolin, Annamaria; Tisi, Maria Chiara; Cuneo, Antonio; Della Porta, Matteo; Trentin, Livio; Turrini, Marco; Gherlinzoni, Filippo; Tafuri, Agostino; Galimberti, Sara; Bocchia, Monica; Cardinali, Valeria; Cilloni, Daniela; Corso, Alessandro; Armiento, Daniele; Rigacci, Luigi; La Barbera, Elettra Ortu; Gambacorti-Passerini, Carlo; Visani, Giuseppe; Vallisa, Daniele; Venditti, Adriano; Selleri, Carmine; Conconi, Annarita.
  • Visco C; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Marcheselli L; Fondazione Italiana Linfomi onlus, Modena, Italy.
  • Mina R; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria Citta'della Salute e della Scienza, Turin, Italy.
  • Sassone M; Lymphoma Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
  • Guidetti A; Hematology and Bone Marrow Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
  • Penna D; Hematology, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico Reggio Emilia, Reggio Emilia, Italy.
  • Cattaneo C; Hematology, Azienda Socio-Sanitaria Territoriale-Spedali Civili, Brescia, Italy.
  • Bonuomo V; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Busca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria Citta'della Salute e della Scienza, Turin, Italy.
  • Ferreri AJM; Lymphoma Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
  • Bruna R; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy.
  • Petrucci L; Hematology, Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy.
  • Cairoli R; Hematology, Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Salvini M; Department of Medicine and Surgery, University of Insubria and Azienda Socio-Sanitaria Territoriale Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy.
  • Bertù L; Department of Medicine and Surgery, University of Insubria and Azienda Socio-Sanitaria Territoriale Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy.
  • Ladetto M; Hematology, Azienda Ospedaliera Santissimi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Pilerci S; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Pinto A; Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale," Naples, Italy.
  • Ramadan S; Division of Onco-Hematology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.
  • Marchesi F; Hematology and Stem Cell Transplant Unit, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy.
  • Cavo M; Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy.
  • Arcaini L; Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo & Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Coviello E; Hematology and bone marrow transplant, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy.
  • Romano A; Hematology, Dipartimento di Chirurgia e Specialità Medico Chirurgiche, Università degli Studi di Catania, Catania, Italy.
  • Musto P; Department of Emergency and Organ Transplantation, Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, Azienda Ospedaliera Universitaria Consorziale Policlinico, Bari, Italy.
  • Massaia M; Hematology, Santa Croce Hospital, Cuneo, Italy.
  • Fracchiolla N; Oncoematologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milano, Italy.
  • Marchetti M; Hematology, Azienda Ospedaliera Santissimi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Scattolin A; Hematology, Ospedale dell'Angelo di Mestre, Venice, Italy.
  • Tisi MC; Hematology, Ospedale San Bortolo, Vicenza, Italy.
  • Cuneo A; Hematology, Azienda Ospedaliero Universitaria Sant'Anna, Ferrara, Italy.
  • Della Porta M; Humanitas Clinical and Research Hospital Istituto di Ricovero e Cura a Carattere Scientifico and Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Trentin L; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Turrini M; Hematology, Ospedale Valduce, Como, Italy.
  • Gherlinzoni F; Hematology, Ospedale Ca' Foncello, Treviso, Italy.
  • Tafuri A; Hematology, University Hospital Sant'Andrea, Sapienza, Rome, Italy.
  • Galimberti S; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Bocchia M; Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy.
  • Cardinali V; Hematology Institute, University of Perugia, Perugia, Italy.
  • Cilloni D; Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Turin, Italy.
  • Corso A; Hematology, Ospedale di Legnano, Milan, Italy.
  • Armiento D; Unit of Hematology, Stem Cell Transplantation, University Campus Bio-Medico, Rome, Italy.
  • Rigacci L; Hematology, Camillo-Forlanini Hospital, Rome, Italy.
  • La Barbera EO; Unità Operativa Complessa Ematologia con Trapianto, Ospedale Santa Maria Goretti, Latina, Italy.
  • Gambacorti-Passerini C; Department of Hematology, Università degli Studi di Milano-Bicocca, Milan, Italy.
  • Visani G; Dipartimento di OncoEmatologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy.
  • Vallisa D; Hematology, Ospedale di Piacenza, Piacenza, Italy.
  • Venditti A; Department of Biomedicine and Prevention, University Tor Vergata Rome, Rome, Italy.
  • Selleri C; Department of Medicine, Hematology, University of Salerno, Ospedale San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • Conconi A; Hematology, Ospedale degli Infermi, Biella, Italy.
Blood Adv ; 6(1): 327-338, 2022 01 11.
Article in English | MEDLINE | ID: covidwho-1622201
ABSTRACT
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin's lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lymphoma Type of study: Controlled clinical trial / Diagnostic study / Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Limits: Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Blood Adv Year: 2022 Document Type: Article Affiliation country: BLOODADVANCES.2021005691

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lymphoma Type of study: Controlled clinical trial / Diagnostic study / Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Limits: Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Blood Adv Year: 2022 Document Type: Article Affiliation country: BLOODADVANCES.2021005691